Evidence map›Paper›PMID 30647123›Full record

ArticleClinical chemistry2019

Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS.

Tiffany A Freed, Josef Coresh, Lesley A Inker, Douglas R Toal, Regis Perichon, Jingsha Chen, Kelli D Goodman, Qibo Zhang, Jessie K Conner, Deirdre M Hauser and 8 more

Abstract read
In one paragraph

Article in Clinical chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Analytical Validation of GFRDiagnostics (Basel, Switzerland) · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Tiffany A FreedMetabolon, Inc., Morrisville, NC.
Josef CoreshDepartments of Epidemiology, Medicine and Biostatistics, Johns Hopkins University, Bloomberg School of Public Health and School of Medicine, Baltimore, MD.
Lesley A InkerDivision of Nephrology, Tufts Medical Center, Boston, MA.
Douglas R ToalMetabolon, Inc., Morrisville, NC.
Regis PerichonMetabolon, Inc., Morrisville, NC.
Jingsha ChenDepartments of Epidemiology, Medicine and Biostatistics, Johns Hopkins University, Bloomberg School of Public Health and School of Medicine, Baltimore, MD.
Kelli D GoodmanMetabolon, Inc., Morrisville, NC.
Qibo ZhangMetabolon, Inc., Morrisville, NC.
Jessie K ConnerMetabolon, Inc., Morrisville, NC.
Deirdre M HauserMetabolon, Inc., Morrisville, NC.
Kate E T VroomMetabolon, Inc., Morrisville, NC.
Maria L OyaskiMetabolon, Inc., Morrisville, NC.
Jacob E WulffMetabolon, Inc., Morrisville, NC.
Gudný EiríksdóttirIcelandic Heart Association, Kopavogur, Iceland.
Vilmundur GudnasonIcelandic Heart Association, Kopavogur, Iceland.
Vicente E TorresDepartment of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Lisa A FordMetabolon, Inc., Morrisville, NC; lford@metabolon.com ALevey@tuftsmedicalcenter.org.
Andrew S LeveyDivision of Nephrology, Tufts Medical Center, Boston, MA; lford@metabolon.com ALevey@tuftsmedicalcenter.org.

Funding

THE PURPOSE OF MODIFICATION TO(1)INCREASE EFFORT OF OPTION 2 AND OPTION 3 FOR ICN01AG12100 · NIA · ICELANDIC HEART ASSOCIATION · PI GUDNASON, VILMUNDUR · 2007 to 2012
$18.4M
Pilot and FeasibilityP30DK090728 · NIDDK · MAYO CLINIC ROCHESTER · PI TORRES, VICENTE E · 2010 to 2019
$11.8M
RENIN ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF ADPKDR01DK044863 · NIDDK · MAYO CLINIC ROCHESTER · PI TORRES, VICENTE E · 1991 to 2019
$4.5M
Estimating GFR from a Panel of Endogenous Filtration Markers (Panel eGFR)R01DK097020 · NIDDK · TUFTS MEDICAL CENTER · PI LEVEY, ANDREW S · 2012 to 2014
$1.9M
AGES STUDY-THE REYKJAVIK STUDY OF HEALTHY AGING FOR THE NEW MILLENNIUM-26012100N01AG012100 · NIA · ICELANDIC HEART ASSOCIATION · 2002 to 2004
–
NIA NIH HHS N01AG12100NIDDK NIH HHS P30 DK090728NIDDK NIH HHS R01 DK044863NIDDK NIH HHS R01 DK097020
6 · The paper itself

Abstract

backgroundClinical practice guidelines recommend estimation of glomerular filtration rate (eGFR) using validated equations based on serum creatinine (eGFRcr), cystatin C (eGFRcys), or both (eGFRcr-cys). However, when compared with the measured GFR (mGFR), only eGFRcr-cys meets recommended performance standards. Our goal was to develop a more accurate eGFR method using a panel of metabolites without creatinine, cystatin C, or demographic variables.

methodsAn ultra-performance liquid chromatography-tandem mass spectrometry assay for acetylthreonine, phenylacetylglutamine, pseudouridine, and tryptophan was developed, and a 20-day, multiinstrument analytical validation was conducted. The assay was tested in 2424 participants with mGFR data from 4 independent research studies. A new GFR equation (eGFRmet) was developed in a random subset (n = 1615) and evaluated in the remaining participants (n = 809). Performance was assessed as the frequency of large errors [estimates that differed from mGFR by at least 30% (1 - P

resultsThe assay had a mean imprecision (≤10% intraassay, ≤6.9% interassay), linearity over the quantitative range (

conclusionsThe new eGFRmet equation could serve as a confirmatory test for GFR estimation.

Indexed as

Glomerular Filtration RateAdultAgedAged, 80 and overChromatography, LiquidFemaleGlutamineHumansMaleMiddle AgedPseudouridineReproducibility of ResultsTandem Mass SpectrometryThreonineTryptophanGlutamineN-acetylthreoninephenylacetylglutaminePseudouridineThreonineTryptophan

Identifiers

PMID30647123
PMCPMC6646882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.